Prince Harry embarks on a new courtroom battle against British tabloids in his case against Rupert Murdoch’s News Group ...

Lehigh University bioenginering researcher Tomas Gonzalez-Fernandez recently secured funding through the National Science ...

Since two groundbreaking treatments were approved in late 2023, only a handful of patients have been able to access the ...

The global gene therapy market size was valued at USD 6.30 billion in 2024 and is projected to reach from USD 7.47 billion in ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. We've got lots ...

MaxCyte Inc. (NASDAQ: MXCT) is a global developer of next-generation cell therapies. They provide crucial technology for cell ...

The "CRISPR-based Gene Editing Market by Product & Service, by Application, by End-User, and By Region" report has been added ...

BizTimes Media’s 24th annual Economic Trends event on Thursday featured insights and predictions from an economist, local business leaders and an academic ...

Advances in CRISPR technologies promise to accelerate the burgeoning pipeline of gene-editing therapies and broaden access to these disease-altering therapies.

The company expects to submit a biologics license application for NTLA-2002 in 2026 and potentially launch it in the US in 2027.

Ongoing launch of CASGEVY® continues to gain momentum--2025 is poised to be a catalyst-rich year with key updates across several ...

Beam Therapeutics shows promise in gene therapy for sickle cell disease, but it also has high risks and market expectations.